LNSR Quote, Financials, Valuation and Earnings

Ainos has a net margin of -193.13% compared to LENSAR's net margin of -3093.98%. LENSAR's return on equity of -464.33% beat Ainos's return on equity of -82.37%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 22.75%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that LENSAR has higher upside potential than Ainos, analysts believe LENSAR is more attractive than Ainos.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 2.202, suggesting its more volatile than the S&P 500 by 120.24%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $14.2M, which are larger than Ainos quarterly revenues of $106.2K. LENSAR's net income of -$27.3M is lower than Ainos's net income of -$3.3M. Notably, LENSAR's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.49x versus 56.59x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

icad has a net margin of -193.13% compared to LENSAR's net margin of -17.09%. LENSAR's return on equity of -464.33% beat icad's return on equity of -17.16%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 22.75%. On the other hand icad has an analysts' consensus of $3.75 which suggests that it could fall by -2.09%. Given that LENSAR has higher upside potential than icad, analysts believe LENSAR is more attractive than icad.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison icad has a beta of 1.379, suggesting its more volatile than the S&P 500 by 37.881%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. icad offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. icad pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $14.2M, which are larger than icad quarterly revenues of $4.9M. LENSAR's net income of -$27.3M is lower than icad's net income of -$833K. Notably, LENSAR's price-to-earnings ratio is -- while icad's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.49x versus 5.19x for icad. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -193.13% compared to LENSAR's net margin of -348.97%. LENSAR's return on equity of -464.33% beat Intelligent Bio Solutions's return on equity of -149.7%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 22.75%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 531.58%. Given that Intelligent Bio Solutions has higher upside potential than LENSAR, analysts believe Intelligent Bio Solutions is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $14.2M, which are larger than Intelligent Bio Solutions quarterly revenues of $728.9K. LENSAR's net income of -$27.3M is lower than Intelligent Bio Solutions's net income of -$2.5M. Notably, LENSAR's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.49x versus 2.84x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -193.13% compared to LENSAR's net margin of -63.81%. LENSAR's return on equity of -464.33% beat Standard BioTools's return on equity of -26.52%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 22.75%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 115.91%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $14.2M, which are smaller than Standard BioTools quarterly revenues of $40.8M. LENSAR's net income of -$27.3M is lower than Standard BioTools's net income of -$26M. Notably, LENSAR's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.49x versus 2.43x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.